No Data
No Data
60 Degrees Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
60 Degrees Pharmaceuticals GAAP EPS of -$18.55
Express News | 60 Degrees Pharmaceuticals Says FY 2024 Net Product Revenues Increased 140% To $607,6000 On Growth From Domestic Commercial Sales Of ARAKODA
Analysts' Opinions Are Mixed on These Healthcare Stocks: Lucid Diagnostics (LUCD), LENSAR (LNSR) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
10-K: Annual report
IntegriChain Hosts Revenue Analytics Collaborative Summit